Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

PerkinElmer Q4 Sales Inch Up Marginally, Issues Q1 FY22 Guidance Ahead Of Consensus

PerkinElmer Inc's (NYSE:PKIQ4 revenues increased 1% Y/Y (down 9% organically) to $1.36 billion, beating the consensus of $1.29 billion.

  • In January, the Company anticipated reported and organic revenue growth of approximately -1% and -12%, respectively.
  • Discovery & Analytical Solutions posted $655 million in revenues, +30% (9% organic).
  • Diagnostics segment sales fell 17% Y/Y (-20% organically) to $709 million. On a non-COVID-19-related basis, revenues were up 14% Y/Y organically.
  • On a conference call, PerkinElmer CFO Jamey Mock noted non-COVID-19-related revenues were up 11% Y/Y while COVID-19-related testing contributed $336 million in Q4.
  • However, COVID-19-related revenues were down more than $200 million year over year.
  • He added that the firm saw strong demand for its COVID-19 PCR tests and extraction kits during Q4, especially in December amid the omicron surge.
  • Adjusted EPS of Q4 declined 35% to $2.56, though beating the consensus of $2.20 
  • Guidance: For Q1 FY22, PerkinElmer expects revenues of $1.17 billion - $1.19 billion and adjusted EPS of $2.05 to $2.10, compared to the consensus of $1.06 billion and $1.51, respectively.
  • The Company reaffirms its FY22 sales of $4.42 billion - $4.50 billion (consensus of $4.32) and adjusted EPS of $6.80 - $7.00 (consensus of $6.60). 
  • On the conference call, the Company reaffirmed its COVID-19-related revenues of at least $400 million for 2022.
  • Price Action: PKI shares are trading higher by 0.29% at $175.00 during premarket trading on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.